Successful Treatment with Selpercatinib for Ectopic Cushing’s Syndrome Due to Medullary Thyroid Cancer
Selpercatinib, a RET kinase inhibitor, is an effective treatment for patients with medullary thyroid cancer with RET mutations. In this paper, we present the case of a 62-year-old man with ectopic Cushing’s syndrome due to medullary thyroid cancer who received treatment with selpercatinib. Six month...
Main Authors: | Oskar Ragnarsson, Marta Piasecka, Andreas Hallqvist |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-05-01
|
Series: | Current Oncology |
Subjects: | |
Online Access: | https://www.mdpi.com/1718-7729/29/5/282 |
Similar Items
-
Is ectopic Cushing’s syndrome underdiagnosed in patients with small cell lung cancer?
by: Marta Piasecka, et al.
Published: (2022-08-01) -
Medullary Thyroid Carcinoma with Ectopic Adrenocorticotropic Hormone Syndrome
by: Hong Seok Choi, et al.
Published: (2014-03-01) -
Rapid and long-lasting response to selpercatinib of paraneoplastic Cushing’s syndrome in medullary thyroid carcinoma
by: Marine Sitbon, et al.
Published: (2023-01-01) -
Case Report: A Challenging Localization of a Pulmonary Ectopic ACTH-Secreting Tumor in a Patient With Severe Cushing’s Syndrome
by: Andreea Liliana Serban, et al.
Published: (2021-07-01) -
Cushing-type ectopic pituitary adenoma with unusual pathologic features
by: Kristopher T. Kimmell, MD, et al.
Published: (2014-06-01)